| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3847892 | American Journal of Kidney Diseases | 2015 | 9 Pages |
Abstract
Pentoxifylline did not significantly modify ESA hyporesponsiveness, but increased hemoglobin concentration. Further studies are warranted to determine whether pentoxifylline therapy represents a safe strategy for increasing hemoglobin levels in patients with CKD with ESA-hyporesponsive anemia.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
David W. MBBS, DMed (Res), PhD, Elaine M. BSc, MBiostat, Sunil V. MBBS, MD, Kim BHealthSc, MHealthEcon, PhD, Alan MBBS, PhD, Philip BEc, MEc, PhD, Paolo MD, Stephen P. MBBS, PhD, Alicia T. BSc, MPH, Eugenie MBBS, PhD, Vlado MBBS, PhD, Donna BA, BAppSc,